Reducing Neuroinflammation in Psychiatric Disorders: Novel Target of Phosphodiesterase 4 (PDE4) and Developing of the PDE4 Inhibitors by Wang, Chuang et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Reducing Neuroinflammation in Psychiatric Disorders:
Novel Target of Phosphodiesterase 4 (PDE4) and
Developing of the PDE4 Inhibitors
Chuang Wang, Zhen Wang, Mengmeng Li,
Chenli Li, Hanjie Yu, Dongsheng Zhou and
Zhongming Chen
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.69154
Abstract
Multiple lines of evidence support the pathogenic role of neuroinflammation in psy‐
chiatric illness. Cyclic adenosine monophosphate (cAMP) is a critical regulator of 
microglia homeostasis; as the predominant negative modulator of cyclic AMP signal‐
ing within microglia, and phosphodiesterase 4 (PDE4) represents a promising target 
for modulating immune function. The approach for pharmacological manipulation of 
cAMP levels using specifc PDE4 inhibitors provokes an ant-iinflammatory response. 
Specifcally, PDE4 inhibitors have recently emerged as a potential therapeutic strategy for 
neuroinflammatory, neurodegenerative, and psychiatric diseases. Mechanistically, PDE4 
inhibitors produce an anti-inflammatory and neuroprotection effect by increasing the 
accumulation of cAMP and activating protein kinase A (PKA), the signaling pathway of 
which is thought to play an important role in the development of psychiatric disorders. 
This chapter reviews present knowledge of the relationship between neuroinflammation 
and classical psychiatric disorders (major depressive disorder (MDD), bipolar disorder 
(BD), and schizophrenia) and demonstrates the signaling pathways that underlie the use 
of PDE4 inhibitors in neuroinflammation. In addition, among the four subtypes (A-D) 
of PDE4, it remains unclear which one exerts suppressive effects on neuroinflammation. 
Understanding how PDE4 and neuroinflammation interact can reveal pathogenic clues 
and help target new preventive and symptomatic therapies for psychiatric illness. 
Keywords: cyclic adenosine monophosphate (cAMP), phosphodiesterase 4 (PDE4), 
psychiatric disorders, neuroinflammation
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
1. Introduction: the possibility that inflammation is the common 
mediator of psychiatric disorders
Classical psychiatric disorders, including major depressive disorder (MDD), bipolar disor‐
der (BD), and schizophrenia, affect a significant percentage of the world population. More 
recently, inflammatory and immunological abnormalities have been documented in patients 
with classical psychiatric disorders, even though the exact mechanisms underlying this asso‐
ciation are not known. A growing body of evidence suggests that activation of the immune 
response following systemic infection often results in neuroinflammation and consequently 
induces psychiatric symptoms in animal models and humans (as shown in Figure 1) [1–6]. 
Specifically, inflammation in the context of the nervous system termed “neuroinflammation” 
has been reported in patients with psychiatric disorders [7] and is typically associated with 
microglial activation.
Microglia, the resident phagocytes of the CNS, are ubiquitously distributed in the brain and 
are usually the first to be activated in response to tissue damage or brain infections [14]. 
At the same time, microglia are important players in the maintenance and plasticity of 
 neuronal  circuits, contributing to the protection and remodeling of synapses [15–16]. They 
provide ongoing immune surveillance and regulate developmental synaptic pruning [17–18]. 
Microglial activation can be divided into two distinct types: a classical M1 and an alternative 
M2 activation. Proinflammatory cytokines include interleukin-1β (IL-1β), interleukin-2 (IL-2), 
interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), interferon-gamma (IFN-γ), and they are 
secreted primarily by microglia [19–21]; [3]. In the M1 activation, microglial cells may become 
Figure 1. Summary of neuroinflammatory responses and microglial abnormalities observed in psychiatry disorders. 
A large body of evidence [8–13] supports the involvement of neuroinflammatory mechanisms, including microglial 
activation, downregulation of dendritic spines, neurogenesis, and neurotrophic factors in the pathophysiology of 
psychiatric disorders.
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hyperramified or ameboid/phagocytic [22], and may synthesize proinflammatory molecules, 
superoxide radicals, glutamate [23–24], and nitric oxide (NO) and ultimately clear infections 
and repair tissues. Alternatively, M2 activation, which can be triggered by cytokines such as 
IL-4, IL-13, or IL-25 [25]; [22], has been associated with a release of antiinflammatory cyto‐
kines (e.g. IL-10, insulin-growth factor-1(IGF-1), transforming growth factor-β (TGF-β), and 
neurotrophic factors) [22], which facilitate healing and limit neuronal injury [7]. Cytokine 
response phenotypes are classified as either proinflammatory T-helper 1 (Th1) or antiinflam‐
matory T-helper 2 (Th2) according to the immune functions they regulate. The key to neuro‐
inflammation effects on psychiatric disorders appears to lie within the dysregulation of the 
control and release of pro- and antiinflammatory cytokines. In fact, Th1 and Th2, which are 
responsible for pathogen elimination and antibody regulation, respectively, were also found 
to be altered in untreated depressed patients [26]. Microglia activation is one of the mecha‐
nisms by which peripheral immune challenges can alter brain functioning [27, 28]; [1]. In fact, 
patients with psychiatric disorders have been shown to present an increase in serum levels of 
proinflammatory cytokines [29–32]; [8]. Interestingly, investigations involving animal models 
of depression and postmortem dorsal anterior cingulate matter from individuals suffering 
from MDD delineate altered expression of microglial activation markers, as well as chronic‐
ity-dependent fluctuations in microglial concentration in areas of the brain associated with 
mood regulation [33–36]; [10, 13]. Additionally, microglial activation was also greater in the 
ventral prefrontal white matter in individuals who committed suicide [37]. Altogether, these 
studies suggest that microglial activation may be considered as an important marker in MDD.
Bipolar disorder is a severe mood disorder characterized by recurrent episodes of mania fol‐
lowed by depression. The pathophysiology of BD is yet to be well understood, while recent 
studies have indicated that abnormal immunological functions may be a contributing factor 
[38–42]. Recently, positron emission tomography (PET) studies have shown microglial overac‐
tivation in the brain of patients with various psychiatric disorders [43–45]; [9] including bipolar 
disorder [42]. Consistent with the previous studies, it was revealed that in BD, the immune sys‐
tem is chronically activated by microglia, which in turn produces cytokines that render the brain 
to a vulnerable and unstable state, precipitating mood disturbances [45–47]. In fact, higher levels 
of IL-1β were associated with dysfunction and increased suicide risk in patients with BD [48].
Schizophrenia is a chronic and debilitating disorder that affects 0.5–1% of the world population 
[49]. Evidence suggests that the dopamine dysfunction hypothesis [50–51] has defined schizo‐
phrenia for many years, a growing number of research investigations and scientific curiosity 
have developed around the immune system and the role of neuroinflammation in precipitating 
psychotic symptoms in a subset of patients with psychosis [52–55]; [5, 6], providing a detailed 
review of the theories and mechanisms that support a role for inflammation in schizophrenia.
2. Cyclic nucleotide signaling and neuroinflammation
Several mechanisms can account for the high comorbidity of neuroinflammation and psy‐
chiatric disorders. These mechanisms include direct effects of cytokines on the neuronal 
environment or indirect effects via downregulation of cyclic nucleotide signaling [56–58]. 
Reducing Neuroinflammation in Psychiatric Disorders: Novel Target of Phosphodiesterase 4...
http://dx.doi.org/10.5772/intechopen.69154
5
Understanding cyclic nucleotide signaling mechanisms that underlie neuroinflammation and 
psychiatric disorder comorbidity may yield effective pharmaceutical targets that can treat 
both conditions simultaneously beyond traditional antipsychotic drugs. There is growing 
evidence that adenosine cyclic 3,5-monophosphate (cAMP) exerts many of its physiological 
effects by activating cAMP-dependent protein kinase (PKA), which in turn phosphorylates 
and regulates the functions of downstream protein targets including ion channels, enzymes, 
and transcription factors [59]. Specifically, cAMP is a ubiquitous regulator of the inflam‐
matory response and is also a key second messenger that influences glial activity [60, 61]. 
Additionally, recent findings have also suggested that cAMP/cAMP response element- 
binding (CREB)  signaling is closely involved in antiinflammatory responses [62] by suppress‐
ing the activation of glial cells (both microglia and astrocytes), decreasing the production 
of proinflammatory mediators, including tumor necrosis factor (TNF)-α, interleukin (IL)-1β, 
IL-6, IL-12, and nitric oxide, and increasing the expression of antiinflammatory factor IL-10 
[63–65]. Therefore, previous work has shown that the application of cAMP analogs, adeny‐
lyl cyclase (AC) activators, or PDE inhibitors, to increase the levels of intracellular cAMP, 
antagonizes the changes in microglial cell morphology and their production of proinflamma‐
tory cytokines when they are exposed to inflammatory stimuli [66–67]. Intracellular cAMP 
signaling has been well established in the mediation of memory [68–71] and depression-like 
behaviors [72, 73]; [57]). cAMP activates protein kinase A (PKA), which phosphorylates and 
activates the subsequent downstream target CREB protein [74, 75] and is important for medi‐
ating synaptic plasticity [76, 77]; [74]. In addition, increases in cAMP levels during inflam‐
mation inhibit the production of proinflammatory cytokines and stimulate the formation of 
IL-10, an antiinflammatory factor [78, 79]. Conversely, inflammatory molecules, including 
lipopolysaccharide (LPS), interferon (IFN)-γ, and TNF-α, can dramatically reduce cyclic AMP 
levels in microglia, leading to changes in their phenotype and function [80]; [56]. Therefore, 
cAMP/CREB signaling may play a beneficial role in inflammatory responses and apoptosis of 
psychiatric disorders. Given that cAMP levels are regulated by a balance between the activi‐
ties of two enzymes: AC and cyclic nucleotide phosphodiesterase (PDE), the pharmacological 
manipulation using specific PDE inhibitors, in particular, PDE4 inhibitors provoke profound 
antiinflammatory responses [81] and beneficial effects on psychiatric disorders [82]; [57]. 
Selective inhibitors of PDE4 are currently used in clinical practice for the treatment of car‐
diovascular disorders and erectile dysfunction, and other PDE inhibitors are under devel‐
opment for the treatment of CNS and inflammatory disorders. This chapter focuses on the 
development of PDE4 and PDE4 subtype inhibitors which have been reported as treatment 
for neuroinflammation.
3. PDE4 and specific PDE4 subtype inhibitors in neuroinflammation
3.1. PDE4 and the distribution of its subtypes in CNS
PDE4, one of the 11 PDE enzyme families, specifically catalyzes hydrolysis of cyclic AMP 
(cAMP); it has four subtypes (PDE4A–D) with at least 25 splice variants. Detailed analyses of 
the expression pattern of the human PDE4 isogenes have recently appeared [83, 84]. All four 
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subtypes, PDE4A, PDE4B, PDE4C, and PDE4D, are found in most tissues although, notably, 
PDE4C is absent in blood (as shown in Table 1). PDE4 plays a critical role in the control of 
intracellular cAMP concentrations. PDE4 gene members are distributed throughout the brain 
and are expressed in various neurons. PDE4 specifically hydrolyzes cAMP to inactive AMP. 
High levels of cytosolic cAMP lead to the activation of PKA and further induce the phosphor‐
ylation of transcription factors, such as CREB and cAMP-dependent transcription factor-1 
(ATF-1) to drive cAMP-driven genes, which involve in the regulation of proinflammatory 
and antiinflammatory pathways (as shown in Figure 2).However, the differential distribu‐
tion of the four PDE4 subtypes (PDE4A–D) in the brain [85] may be attributed to the different 
regulation of cAMP-mediated signaling in CNS. PDE4A and PDE4D are highly expressed in 
the cortex, olfactory bulb, hippocampal formation, and brainstem, whereas PDE4B is mainly 
expressed in the amygdala, striatum, and hypothalamus [86–88]. By contrast, PDE4C exhibits 
a distribution different from those of PDE4A and PDE4D and appears to be limited to the 
thalamus and cerebellum [89, 90]. Because of the unique distribution of PDE4 isoform and its 
significance in various physiological functions in CNS, PDE4 presents promising pharmaceu‐
tical drug target treatment for psychiatric disorders.
3.2. Traditional PDE4 inhibitors
The search for selective inhibitors of PDE4 as novel antiinflammatory drugs has continued 
for more than 40 years. Recent findings have also suggested that cAMP/CREB/brain-derived 
neurotrophic factor (BDNF) signaling is closely involved in antiinflammatory responses 
[66], depression, and antidepressant actions [91]; [68]. PDE4 inhibition has been a target 
Location Level of expression
PDE4A PDE4B PDE4C PDE4D
Brain ++ ++ ++ ++
Liver ++ ++ ++ ++
Lung ++ ++ ++ ++
Trachea ++ ++ ++ ++
Kidney ++ ++ ++ ++
Placenta ++ ++ ++ ++
Heart ++ ++ ++ ++
Blood ++ ++ − ++
Neutrophils ± ++ − ±
Eosinophils ++ ++ − ++
++, expression.
±, very weak expression.
−, no expression.
Table 1. Expression patterns of mRNAs for the human phosphodiesterase 4 (PDE4) subtype genes.
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of therapeutic drug research since the 1970s, with the prototypic PDE4 inhibitor, rolipram 
being tested in clinical trials in the 1980s [92]. Notably, PDE4 inhibitor rolipram that read‐
ily produces antidepressant-like actions [93, 94], which are associated with increased level 
of cAMP and its downstream targets of cAMP-dependent protein kinase A (PKA), CREB, 
and BDNF [95]; [68]. Therefore, the potential PDE4 inhibitors may be an efficient alternative 
strategy to play antidepressant action especially in depressive disorder induced by inflamma‐
tion. Consistent with this hypothesis, the previous studies have demonstrated that rolipram 
reduces neuroinflammation and promotes axonal regeneration and functional recuperation 
following spinal cord injury [96–98]; [62]. More evidence have shown that PDE4 inhibitor 
rolipram reduces the production of proinflammatory cytokines and modulates the activity 
of cAMP-mediated signaling and thus regulates CREB phosphorylation and the downstream 
effectors [99]; [62, 68], showing that potential PDE4 inhibitors may be suitable to antagonize 
psychiatric disorders. Unfortunately, the development of PDE4 inhibitor rolipram for thera‐
peutic purposes has been hindered by side effects, such as emesis [100, 101]. Based on the 
Figure 2. The antiinflammatory mechanisms of PDE4 and PDE4 subtype inhibitors. cAMP as a regulator of immunity. 
Adenylate cyclases (AC) produce cAMP from adenosin-tri-phosphate (ATP). High levels of cytosolic cAMP lead to the 
activation of protein kinase A (PKA) and further induce the phosphorylation of transcription factors, such as CREB and 
cAMP-dependent transcription factor-1 (ATF-1) to drive cAMP-driven genes. Phosphodiesterase 4 (PDE4) decreases 
intracellular cAMP levels and counterbalances the intracellular cAMP effect. However, PDE4 or subtype inhibitors block 
PDE4 or its subtypes. As PDE4 or subtypes degrade cAMP to AMP, cAMP levels rise during apremilast treatment. 
The elevation of intracellular cAMP leads to the activation of PKA. This results in the phosphorylation and activation 
of transcription factors like CREB and ATF-1. On the other hand, NF-κB is inactivated. This transcriptional regulation is 
responsible for the reduced production of proinflammatory mediators like IL-1β, IL-12, IL-17, IL-22, IL-23, TNF-α, and 
IFN-γ and the increased production of IL-6 and the antiinflammatory mediator IL-10.
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demonstration of significant efficacy in preclinical models, multiple PDE4 inhibitors have 
entered clinical development, and none have reached the market. Roflumilast and apremilast 
have been approved for peripheral inflammatory disorders, such as severe chronic obstruc‐
tive pulmonary disease (COPD) and psoriatic arthritis (PA), respectively; however, their full 
immunomodulatory activity is limited to doses which are estimated to inhibit PDE4 by 50% 
due to the incidence of nausea and emesis at higher exposures. Unfortunately, the two PDE4 
inhibitors (roflumilast and apremilast) approved for peripheral inflammatory disorders lack 
brain penetration and are dose limited by side effects making them unsuitable for modulat‐
ing microglial function. Despite the challenges and complications that have been encoun‐
tered during the development of PDE4 inhibitors, these drugs may provide a genuinely novel 
class of antineuroinflammatory agents, and there are several compounds in development that 
could fulfill that promise.
3.3. The novel potential PDE4 inhibitors
Notably, it has been recently reported that a pyrazolopyridine compound, etazolate, is 
a new-generation selective PDE4 inhibitor and is proven to be of particular significance 
in  neuropsychiatric conditions [102, 103]; [94]. Previous studies reported that etazolate 
belongs to PDE4 inhibitor family and that treatment with etazolate restored cAMP levels 
[66, 94, 103]. In most of the clinical phase II or Phase IIb studies, etazolate has shown that it 
could be a potential candidate for the treatment of Alzheimer’s disease [102]. Additionally, 
in several preclinical studies, etazolate has shown significant antidepressant- and anxio‐
lytic-like effects in acute and chronic rodent models [104, 105]; [66, 103]. Specifically, it 
is reported that the expression of PDE4A, PDE4B, and PDE4D in the hippocampus was 
significantly increased by lipopolysaccharide (LPS) in mice. In addition, an etazolate sig‐
nificantly reversed the elevated IL-1β expression in hippocampus and prefrontal cortex 
induced by LPS [103], indicating significant antineuroinflammatory response. Although 
limited preclinical studies have been conducted on etazolate, the recent clinical trial results 
on its safety and tolerance are encouraging [106]. However, in March 2014, the development 
of the etazolate was stopped as the company transformed into a specialty in vitro diagnos‐
tics company.
Recently, more and more novel selective PDE4 inhibitors (as shown in Table 2) have been 
designed and explored in different rodent models, displaying a safer profile compared to tra‐
ditional agents [107–111]; [66, 75], supporting further evaluation of these novel PDE4 inhibi‐
tors in a clinical setting.
3.4. PDE4 subtype inhibitors
Particular attention has been given to the PDE4 isoforms owing to the antiinflammatory 
effects observed after their inhibition in vitro and in vivo [81]. Of the four major phosphodi‐
esterase 4 (PDE4) subtypes, PDE4A, PDE4B, or PDE4D, all of which are found to some extent 
in every inflammatory cell type studied, could be important regulators of inflammatory pro‐
cesses. Only PDE4C, which is present in the lung [112] but has only rarely and inconsistently 
been reported in any isolated inflammatory cell type, can be eliminated on the basis of its 
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Novel PDE4 inhibitors Chemical structures Active indications Highest status
Etazolate Depression, anxiety, 
traumatic brain injury
Phase 2 clinical to 
discontinued
EPPA-1 In vitro and in vivo anti 
inflammatory potencies
Discovery
GSK256066 Antiinflammatory activities Phase 2 clinical to 
discontinued
LASSBio-448 Antiinflammatory activities Discovery
FFPM Reverses learning and 
memory deficits and 
appears to have potential 
antiinflammatory effects 
with little emetic potential
Discovery
Apremilast Ankylosing spondylitis; 
Atopic dermatitis; Behcet’s 
disease; Hidradenitis 
suppurativa; Psoriasis; 
Psoriatic arthritis; Ulcerative 
colitis
Launched
HT-0712 Cognitive disorder Phase 2 clinical
Roflumilast Alzheimer’s disease; 




Ibudilast Alcoholism; Amphetamine 
dependence; Drug 
dependence; Neuropathic 
pain; Opiate dependence; 
Traumatic brain injury
Phase 2 clinical
Table 2. Development of novel PDE4 inhibitors.
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distribution. This distribution characteristic provides many opportunities for selective thera‐
peutic targeting [113, 114] and the potential to reduce the incidence of side effects attributed 
to PDE4 inhibition. The previous studies revealed that PDE4B might be the critical subtype 
that controls the inflammatory responses [115–117]. The work by Conti’s group [115] identi‐
fied PDE4B to be the primary PDE4 enzyme involved in proinflammatory responses to LPS in 
macrophages and leukocytes. Reports have suggested that mice deficient in PDE4A display 
anxiogenic-like behavior [118], while PDE4B is closely related with neuroinflammation [119]. 
Therefore, subtype selective inhibitors targeting PDE4B are of high interest given the criti‐
cal role PDE4B plays in immune function versus the association of PDE4D with nausea and 
emesis. However, it is difficult to directly link PDE4 inhibitor-mediated efficacy to changes 
specifically in microglial cell function, and even more so whether these effects selectively 
involve PDE4B. The difficulty in establishing these links is because these investigations 
have almost exclusively used pharmacological inhibitors that are administered systemically 
and which show similar affinity toward all PDE4 family members, being designed largely 
to inhibit enzyme activity by binding to the catalytic site. Recently, the crystal structures of 
PDE4B have been exploited to develop subtype-selective PDE4 inhibitors [120]. The novel 
PDE4B inhibitor A33, which has an IC50 of 32 nM against PDE4B1, is 49-fold more selective 
for PDE4B versus PDE4D and does not appreciably inhibit any other PDEs [121]. Specifically, 
A33 inhibits all PDE4B isoforms and is 49-fold more selective toward PDE4B compared with 
PDE4D and does not appreciably inhibit other PDEs [120, 121]. Interestingly, TNF-α levels 
at 6-hour postsurgery of traumatic brain injury (TBI) were significantly reduced by A33, sug‐
gesting that an inflammatory pathway mediated by PDE4B is inhibited with A33 [122]; [115] 
(Jin and Conti; Jin et al.). However, further studies to determine the antineuroinflammatory 
mechanisms of A33 may yield insights into the processes involved in the improvements of 
psychiatric disorders with A33 treatment.
4. Conclusions
A large body of evidence supports the involvement of neuroinflammatory mechanisms in the 
pathophysiology of psychiatric disorders. Drugs that interfere with these mechanisms, such 
as PDE4 inhibitors, could be a novel and important new pathway for the treatment of these 
disorders. Furthermore, continued drug discovery efforts to identify safe and well-tolerated, 
brain-penetrant PDE4 inhibitors are a reflection of the confidence in the rationale for modula‐
tion of this target to produce meaningful therapeutic benefit in a wide range of neurological 
conditions and injury.
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